Skip to main content

Market Overview

Cytokinetics Surges Amid Roth Capital Raising Its Price Target


Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18.

The analyst note cited four facets for its strengthened investment case:

1) "CYTK has shown its prowess in attracting significant partnerships in the form of both Amgen and Astellas,"

2) "each of these partners have approximately the same equity stake in CYTK as well,

3) "a regulatory path forward for tirasemtiv for ALS is expected in the near term and, importantly,

4) "the company has a strong financial footing with 2-3 years of cash on hand with the recently expanded Astellas collaboration (~$150 million pro forma cash)."

Analyst Joseph Pantginis concluded, “While the final trial design for a pivotal study has not yet been agreed upon with the FDA and EMEA, the trial design will likely contain and adaptive design as well as important interim analyses. This should allow CYTK to "titrate" their spending on the ALS study on an "as needed basis".”

Cytokinetics recently traded at $8.03, up 16.4 percent.

Latest Ratings for CYTK

Mar 2021Wolfe ResearchInitiates Coverage OnOutperform
Jan 2021HC Wainwright & Co.MaintainsBuy
Dec 2020Morgan StanleyMaintainsOverweight

View More Analyst Ratings for CYTK
View the Latest Analyst Ratings


Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: Joseph Pantginis Roth CapitalAnalyst Color Health Care Price Target Intraday Update Analyst Ratings General

Latest Ratings

WKHSB. Riley FBRInitiates Coverage On20.0
FCELB. Riley FBRInitiates Coverage On11.0
AAWWTruist SecuritiesInitiates Coverage On95.0
NOGCitigroupInitiates Coverage On17.0
SONSeaport GlobalDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at